Platelet-Activating Factor (PAF) - A Putative Mediator in Inflammatory Tissue Injury

  • Tian-Li Yue
  • Reuven Rabinovici
  • Giora Feuerstein
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 314)


Platelet-activating factor (PAF) is a potent lipid autacoid identified as 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine (figure 1). Originally isolated from immunoglobulin E-stimulated basophils as a potent inducer of platelet aggregation1, it soon became apparent that in addition to activation of platelets, PAF exerts diverse biological actions including stimulation of neutrophils, monocytes, and macrophages, increased vascular permeability, marked hemodynamic effects, and others2. It is now clear that PAF synthesis can be stimulated by various stimuli3 in many different cell types, some of which also release PAF into extracellular milieu. PAF actions are achieved at concentrations as low as 10−12 M in some systems and almost always by 10−9 M, suggesting a role as an intercellular messenger4. These observations have suggested that PAF plays a role both in normal physiological events and a variety of pathological responses. This chapter will emphasize the effects of PAF relevant to inflammatory responses and tissue injury. Some essential biochemical background of PAF will also be outlined.


Acalculous Cholecystitis Acute Acalculous Cholecystitis Lipoxygenase Product Cold Urticaria Inflammatory Tissue Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. Benveniste, P.M. Henson, and C.G. Cochrane, Leukocyte-dependent histamine release from rabbit platelet: The role of IgE basophils and a platelet activating factor, J Exp Med 136: 1356 (1972).PubMedCrossRefGoogle Scholar
  2. 2.
    P. Braquet, L. Touqui, T.Y. Shen, and B.B. Vargaftig, Perspectives in platelet-activating factor research, Pharmacol Rev 39: 97 (1987).PubMedGoogle Scholar
  3. 3.
    F. Snyder, Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators, Am J Physiol 259:C697 (1990).Google Scholar
  4. 4.
    S.M. Prescott, G.A. Zimmerman, and T.M. Mclntyre, Platelet-activating factor, J Biol Chem 265: 17381 (1990).PubMedGoogle Scholar
  5. 5.
    P.V. Peplow, and D.P. Mikhailidis, Platelet-activating factor (PAF) and its relation to prostaglandins and leukotrienes and other aspects of arachidonate metabolism, Prostaglandins Leukotrienes Essential Fatty Acids 41: 71 (1990).CrossRefGoogle Scholar
  6. 6.
    T.L. Yue, P.G. Lysko, and G. Feuerstein, Production of platelet-activating factor from rat cerebellar granule cells in culture, J. Neurochem 54: 1809 (1990).PubMedCrossRefGoogle Scholar
  7. 7.
    R.L. Wykle, B. Malone, and F. Snyder, Enzymatic synthesis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid, J Biol Chem 255: 10256 (1980).PubMedGoogle Scholar
  8. 8.
    G. Camussi, C. Tetta, F. Bussolino, and C. Baglion, Antiinflammatory peptides (antiflammins) inhibit synthesis of platelet-activating factor neutrophil aggregation and Chemotaxis, and intradermal inflammatory reactions, J Exp Med 171: 913 (1990).PubMedCrossRefGoogle Scholar
  9. 9.
    S.B. Hwang, Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms, J Lip Mediators 2: 123 (1990).Google Scholar
  10. 10.
    T.L. Yue, M.M. Gleason, J. Hallenbeck, and G. Feuerstein, Characterization of platelet-activating factor-induced elevation of cytosolic free-calcium level in neurohybrid NCB-20 cells, Neurosci (1991). (In press).Google Scholar
  11. 11.
    D.W.H. Riches, S.K. Young, J.F. Seccombe, J.E. Henson, K.L. Clay, and P.M. Henson, The subcellular distribution of platelet-activating factor in stimulated human neutrophils, J Immunol 145: 3062(1990).PubMedGoogle Scholar
  12. 12.
    D. Bratton and P.M. Henson, Cellular origins of PAF, in: “Platelet-activating factor and human disease/” P.J. Baarnes, C.P. Page and P.M. Henson, eds., Blackwell, Oxford, London (1989).Google Scholar
  13. 13.
    P. Braquet, M.P. Braquet, R.H. Bourgain, F. Bussolino, and D. Hosford, PAF cytokine auto-generated feedback networks in microvascular immune injury. J Lip Mediators 1: 75 (1989).Google Scholar
  14. 14.
    S.M. Prescott, T.M. Mclntyre, and G.A. Zimmerman, The role of platelet-activating factor in endothelial cells, Thromb Haemost 64: 99 (1990).PubMedGoogle Scholar
  15. 15.
    A.H. Lin, D.R. Morton, and R.R. Gorman, Acetyl-glyceryl-ester-phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes, J Clin Invest 70: 1058 (1982).PubMedCrossRefGoogle Scholar
  16. 16.
    C. Dubois, E. Bissonnette, and M. Rola-Pleszczynski, Platelet-activating factor (PAF) enhances tumor necrosis factor production by alvaolar macrophages, J Immunol 143: 964 (1989).PubMedGoogle Scholar
  17. 17.
    R. Barthelson and F. Valone, Interaction of platelet-activating factor with interferon-γ in the stimulation of interleukin-1 production by human monocytes, J Allergy Cin Immunol 86: 193 (1990).CrossRefGoogle Scholar
  18. 18.
    J. Rose, R. Barthelson, R. Debs, and F. Valone, Selective monocyte activation by a 2-0-methoxy analog of platelet-activating factor, Clin Res 37: 418A (1989).Google Scholar
  19. 19.
    B. Bonavida, J.M. Mencia-Huerta, and P. Braquet, Effects of platelet-activating factor on peripheral blood monocytes: induction and priming for TNF secretion, J Lipid Mediator 2 (suppl): S65(1990).Google Scholar
  20. 20.
    M. Rola-Pleszczynski, Priming of human monocytes with PAF augments their production of tumor necrosis factor, J Lipid Mediator 2 (suppl): S77 (1990).Google Scholar
  21. 21.
    R. Barthelson and F. Valone, Platelet-activating factor (PAF)-induced interleukin-1 beta (IL-1) messenger RNA, Clin Res 38: 111A (1990).Google Scholar
  22. 22.
    M. Rola-Pleszczynski, B. Pignol, C. Pouliot, and P. Braquet, Inhibition of human lymphocyte proliferation and interleukin-2 production by platelet-activating factor (PAF-acether): reversed by a specific antagonist: BN52021, Biochem Biophys Res Commun 142: 754 (1987).PubMedCrossRefGoogle Scholar
  23. 23.
    M. Pretolani, J. Lefort, C. Dumarey and B.B. Vargaftig, Role of lipoxygenase metabolites for the hyperresponsiveness to PAF-acether of lungs from actively sensitized guinea-pigs, J Pharmacol Exp Ther 248: 355 (1989).Google Scholar
  24. 24.
    N.F. Voelkel, S. Worthen, J.T. Reeves, P.M. Henson, and R.C. Murphy, Nonimmunological production of leukotrienes induced by platelet-activating factor, Science 218: 286 (1982).PubMedCrossRefGoogle Scholar
  25. 25.
    W. Hsueh, F. Gonzalez-Crussi, and J.L. Arroyave, Release of leukotriene C4 by isolated, perfused rat small intestine in response to platelet-activating factor, J Clin Invest 78: 108 (1986).PubMedCrossRefGoogle Scholar
  26. 26.
    P.J. Piper, and A.G. Stewart, Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4, J Br Pharmacol 88: 595 (1986).Google Scholar
  27. 27.
    B. Pignol, S. Henane, J.M. Mencia-Huerta, and P. Braquet, Effect of long term treatment with platelet-activating factor on cytokine production by rat spleen cells, Int Arch Appl Immunol 88: 161 (1989).CrossRefGoogle Scholar
  28. 28.
    M. Paubert-Braquet, D. Hosford, P. Klotz, J. Guibaud, and P. Braquet, Tumor necrosis factor alpha’ primes’ the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins, J Lipid Mediator 2 (suppl): S1 (1990).Google Scholar
  29. 29.
    F. Bussolino, G. Camussi, C. Tetta, G. Barbarino, A. Bosia, and C. Baglioni, Selected cytokines promote the synthesis of platelet-activating factor in vascular endothelial cells: comparison between tumor necrosis factor alpha and beta and interleukin-1, J Lipid Mediator 2 (suppl): S15 (1990).Google Scholar
  30. 30.
    N. Perico, and G. Remuzzi, Role of platelet-activating factor in renal immune injury and proteinuria, Am J Nephrol 10 (suppl 1): 98 (1990).PubMedCrossRefGoogle Scholar
  31. 31.
    D. Schlondorff, P. Goldwasser, R. Neuwirth, A. Satriano, and K.L. Clay, Production of platelet-activating factor in glomeruli and cultured glomerular mesangial cells, Am J Phyaiol 250: F1123 (1986).Google Scholar
  32. 32.
    E. Pirotzky, J. Bidault, C. Burtin, M.C. Gubler, and J. Benveniste, Release of platelet-activating factor, slow reacting substance and vasoactive amines from isolated rat kidneys, Kidney Int 25: 404(1984).PubMedCrossRefGoogle Scholar
  33. 33.
    G. Camussi, C. Tetta, R. Coda, G. Segoloni, and A. Vercellone, Platelet-activating factor-induced lose of glomerular anionic charges, Kidney Int 25: 73 (1984).PubMedCrossRefGoogle Scholar
  34. 34.
    Z. Ackerman, F. Karmeli, M. Ligumsky, and D. Rachmilewitz, Enhanced gastric and duodenal platelet-activating factor and leukotriene generation in duodenal ulcer patients, Scand J Gastroenterol 25: 925 (1990).PubMedCrossRefGoogle Scholar
  35. 35.
    D. Rachmilewitz, F. Karmeli, and R. Eliakim, Platelet-activating factor — a possible mediator in the pathogenesis of ulcerative colitis, Scand J Gastroenterol 25 (suppl 172): 19 (1990).CrossRefGoogle Scholar
  36. 36.
    A. Dembinska-Kiec, B.A. Peskar, M.K. Muller, and M.A. Peskar, The effects of platelet-activating factor on flow rate and eicosanoid release in the isolated perfused rat gastric vascular bed, Prostaglandins 37: 69 (1989).PubMedCrossRefGoogle Scholar
  37. 37.
    J.L. Wallace, and B.J.R. Whittle, Profile of gastrointestinal damage induced by platelet-activating factor, Prostaglandins 32: 137 (1986).PubMedCrossRefGoogle Scholar
  38. 38.
    J.L. Wallace, CM. Hogaboam, and G.W. McKnight, Platelet-activating factor mediates gastric damage induced by hemorrhagic shock, Am J Physiol 259: G140 (1990).PubMedGoogle Scholar
  39. 39.
    M.S. Caplan, X.M. Sun, and W. Hsueh, Hypoxia causes ischemic bowel necrosis in rats: the role of platelet-activating factor (PAF-acether), Gastroenterol 99: 979 (1990).Google Scholar
  40. 40.
    D. Kaminski, C.H. Andrus, and D. German, The role of prostanoids in the production of acute acalculous cholecystitis by platelet-activating factor, Ann Surg 212: 455 (1990).PubMedCrossRefGoogle Scholar
  41. 41.
    G. Emanuelli, G. Montrucchio, and E. Grain, Experimental acute pancreatitis induced by platelet-activating factor in rabbits, Am J Pathol 134: 314 (1989).Google Scholar
  42. 42.
    G. Camussi, and J.R. Brentjens, The role of platelet-activating factor in inflammation, in: “Platelet-activating factor and related lipid mediators,” F. Snyder, ed., Plenum, New York (1987).Google Scholar
  43. 43.
    G. Camussi, and J.R. Brentjens, Inhalation of horseradish peroxidase by rabbits with specific IgE antibodies results in release into the circulation of platelet-activating factor and in lung lesions, Clin Immunol Immunopathol 34: 332 (1985).CrossRefGoogle Scholar
  44. 44.
    J. Mcmanus, and R.N. Pinckard, Kinetics of acetyl glycerol ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit, Am J Pathol 121: 55 (1985)PubMedGoogle Scholar
  45. 45.
    G. Camussi, I. Pawlowski, C. Tetta, C. Roffinello, M. Alberton, J. Brentjens, and S. Andres, Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor, Am J Pathol 112: 78 (1983).PubMedGoogle Scholar
  46. 46.
    J.M. Mencia-Huerta, D. Hosford, and P. Braquet, Acute and long-term pulmonary effects of platelet-activating factor, Clin Exp Allergy 19: 125 (1989).PubMedCrossRefGoogle Scholar
  47. 47.
    G. Montrucchio, G. Alloatti, F. Mariano, R. Paulis, and G. Camussi, Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart, Am J Pathol 137: 71 (1990).PubMedGoogle Scholar
  48. 48.
    G. Montrucchio, G. Alloatti, C. Tetta, R. DeLuca, R.N. Saunders, G. Emanuelli, and G. Camussi, Release of platelet-activating factor (PAF) from ischemic-reperfused rabbit heart, Am J Physiol 2456:H11236 (1989).Google Scholar
  49. 49.
    P. Braquet, D. Hosford, B. Spinnewyn, D. Dunerger, N.G. Bazan, and E. Pirotzky, The therapeutic potential of Ginkgolides and other PAF antagonists in cerebral ischemia, in: “Platelet-activating factor (PAF) and diseases,” K. Saito and D.J. Hanahan, eds., Int Med Publisher, Tokyo (1989).Google Scholar
  50. 50.
    P.J. Lindsberg, T.L. Yue, K.U. Frerichs, J.M. Hallenbeck, and G. Feuerstein, Evidence for platelet-activating factor as a novel mediator in experimental stroke in rabbits, Stroke 21: 1452 (1990).PubMedCrossRefGoogle Scholar
  51. 51.
    P. Kubes, G. Ibbotson, J. Russell, J.L. Wallace, and D.N. Granger, Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence, Am J Physiol 259:G300 (1990).Google Scholar
  52. 52.
    G.L. Stahl, Z. Terashita, and A. Lefer, Role of platelet-activating factor in propagation of cardiac damage during myocardial ischemia, J Pharmacol Exp Ther 244: 898 (1988).PubMedGoogle Scholar
  53. 53.
    G. Feuerstein, T.L. Yue, and P.G. Lysko, Platelet-activating factor a putative mediator in central nervous system injury?, Stroke 21 (suppl III): 90 (1990).Google Scholar
  54. 54.
    H.E.P. Bazan, S.T.K. Reddy, J.M. Woodland, and N.G. Bazan, The accumulation of platelet-activating factor in the injured cornea may be interrelated with the synthesis of lipoxygenase products, Biochem Biophys Res Commun 149: 915 (1987).PubMedCrossRefGoogle Scholar
  55. 55.
    A.I. Mallet, and F.M. Cunningham, Structural identification of platelet-activating factor in psoriatic scale, Biochem Biophys Res Commun 126: 192 (1985).PubMedCrossRefGoogle Scholar
  56. 56.
    K.E. Grandel, R.S. Farr, A.A. Wanderer, T.C. Eisenstaat, and S.I. Wasserman, Association of platelet-activating factor with primary acruired cold urticaria, N Engl J Med 313: 405 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Tian-Li Yue
    • 1
  • Reuven Rabinovici
    • 1
  • Giora Feuerstein
    • 1
  1. 1.Department of PharmacologySmithKline Beecham PharmaceuticalsKing of PrussiaUSA

Personalised recommendations